Sino Biopharmaceutical (SMZ1) Stock Forecast & Price Target
SMZ1 Analyst Ratings
Strong Buy
10Buy0Hold0Sell
Based on 10 analysts giving stock ratings to Sino Biopharmaceutical in the past 3 months
SMZ1 Stock 12 Month Forecast
Average Price Target
CHF 0.94▲(86.41% Upside)Based on 10 Wall Street analysts offering 12 month price targets for Sino Biopharmaceutical in the last 3 months. The average price target is CHF 0.94 with a high forecast of CHF 1.13 and a low forecast of CHF 0.73. The average price target represents a 86.41% change from the last price of CHF 0.50.
Past 12 Months12 Month ForecastDec2025Sep2026
HighCHF 1.13
AverageCHF 0.94
LowCHF 0.73
Highest Price TargetHighestCHF 1.13Average Price TargetCHF 0.94Lowest Price TargetLowestCHF 0.73
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
 Unknown AnalystNot Ranked | UBS | CHF 0.81 | buy | 60.73%Upside | Reiterated | 10/28/26 | ||
| Unknown AnalystNot Ranked | Guosheng Securities | CHF 0.86 | buy | 71.17%Upside | Reiterated | 09/04/26 | ||
| Unknown AnalystNot Ranked | Shenwan Hongyuan | CHF 1.09 | buy | 117.09%Upside | Reiterated | 08/26/26 | ||
| Unknown AnalystNot Ranked | China Merchants Securities | CHF 1.03 | buy | 104.57%Upside | Reiterated | 08/25/26 | ||
| Unknown AnalystNot Ranked | BOCOM International Holdings Company | CHF 0.81→CHF 1.05 | buy | 108.74%Upside | Reiterated | 08/21/26 | ||
| Unknown AnalystNot Ranked | CMB International Securities | CHF 0.91 | buy | 81.61%Upside | Reiterated | 08/21/26 | ||
| Unknown AnalystNot Ranked | Citi | CHF 1.05→CHF 1.13 | buy | 125.44%Upside | Reiterated | 08/20/26 | ||
| Unknown AnalystNot Ranked | CICC | CHF 0.93 | buy | 85.78%Upside | Reiterated | 08/20/26 | ||
| Alexis Yan | Morgan Stanley | CHF 0.82 | buy | 62.82%Upside | Reiterated | 08/19/26 | ||
| Unknown AnalystNot Ranked | Daiwa | CHF 0.73 | buy | 46.12%Upside | Reiterated | 08/12/26 | ||
| Unknown AnalystNot Ranked | UOB Kay Hian | CHF 0.76 | buy | 50.30%Upside | Reiterated | 07/24/26 | ||
| Unknown AnalystNot Ranked | Nomura | CHF 0.87 | buy | 72.42%Upside | Reiterated | 07/24/26 | ||
| Unknown AnalystNot Ranked | HSBC | CHF 0.89 | buy | 77.43%Upside | Reiterated | 07/10/26 | ||
| Unknown AnalystNot Ranked | Citic Securities | CHF 0.94 | buy | 87.87%Upside | Reiterated | 06/25/26 | ||
| Mark Kong CFA | DBS | CHF 0.68 | buy | 35.68%Upside | Initiated | 05/20/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Unknown AnalystNot Ranked | 10/28/26 | CHF 0.81 | buy | 60.73%Upside | Reiterated | UBS | ||
| Unknown AnalystNot Ranked | 09/04/26 | CHF 0.86 | buy | 71.17%Upside | Reiterated | Guosheng Securities | ||
| Unknown AnalystNot Ranked | 08/26/26 | CHF 1.09 | buy | 117.09%Upside | Reiterated | Shenwan Hongyuan | ||
| Unknown AnalystNot Ranked | 08/25/26 | CHF 1.03 | buy | 104.57%Upside | Reiterated | China Merchants Securities | ||
| Unknown AnalystNot Ranked | 08/21/26 | CHF 0.81→CHF 1.05 | buy | 108.74%Upside | Reiterated | BOCOM International Holdings Company | ||
| Unknown AnalystNot Ranked | 08/21/26 | CHF 0.91 | buy | 81.61%Upside | Reiterated | CMB International Securities | ||
| Unknown AnalystNot Ranked | 08/20/26 | CHF 1.05→CHF 1.13 | buy | 125.44%Upside | Reiterated | Citi | ||
| Unknown AnalystNot Ranked | 08/20/26 | CHF 0.93 | buy | 85.78%Upside | Reiterated | CICC | ||
| Alexis Yan | 08/19/26 | CHF 0.82 | buy | 62.82%Upside | Reiterated | Morgan Stanley | ||
| Unknown AnalystNot Ranked | 08/12/26 | CHF 0.73 | buy | 46.12%Upside | Reiterated | Daiwa | ||
| Unknown AnalystNot Ranked | 07/24/26 | CHF 0.76 | buy | 50.30%Upside | Reiterated | UOB Kay Hian | ||
| Unknown AnalystNot Ranked | 07/24/26 | CHF 0.87 | buy | 72.42%Upside | Reiterated | Nomura | ||
| Unknown AnalystNot Ranked | 07/10/26 | CHF 0.89 | buy | 77.43%Upside | Reiterated | HSBC | ||
| Unknown AnalystNot Ranked | 06/25/26 | CHF 0.94 | buy | 87.87%Upside | Reiterated | Citic Securities | ||
| Mark Kong CFA | 05/20/26 | CHF 0.68 | buy | 35.68%Upside | Initiated | DBS |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Sino Biopharmaceutical
3 Months
Success Rate1/2 ratings generated profit
50%
Average Return
0.00%
Copying Alexis Yan's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of 0.00% per trade.
1 Year
Success Rate0/2 ratings generated profit
0%
Average Return
-4.40%
Copying Alexis Yan's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -4.40% per trade.
2 Years
Success Rate0/2 ratings generated profit
0%
Average Return
-4.40%
Copying Alexis Yan's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -4.40% per trade.
SMZ1 Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 3 | 9 | 14 | 12 | 7 |
| Buy | 1 | 3 | 4 | 5 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 4 | 12 | 18 | 17 | 10 |
In the current month, SMZ1 has received 10 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. SMZ1 average Analyst price target in the past 3 months is 0.94.
SMZ1 Financial Forecast
HighCHF 0.01
ConsensusCHF 0.01
LowCHF 0.01
SMZ1 Earnings Forecast
Next quarter’s earnings estimate for SMZ1 is CHF 0.01 with a range of CHF 0.01 to CHF 0.01. The previous quarter’s EPS was CHF 0.02. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighCHF 2.09B
ConsensusCHF 2.07B
LowCHF 2.05B
SMZ1 Sales Forecast
Next quarter’s sales forecast for SMZ1 is CHF 2.07B with a range of CHF 2.05B to CHF 2.09B. The previous quarter’s sales results were CHF 2.33B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
SMZ1 Stock Forecast FAQ
What is CH:SMZ1’s average 12-month price target, according to analysts?
Based on analyst ratings, Sino Biopharmaceutical’s 12-month average price target is CHF0.94.
What is CH:SMZ1’s upside potential, based on the analysts’ average price target?
Sino Biopharmaceutical has 86.41% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Sino Biopharmaceutical a Buy, Sell or Hold?
Sino Biopharmaceutical has a consensus rating of Strong Buy, which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
What is Sino Biopharmaceutical’s share price target?
The average share price target for Sino Biopharmaceutical is CHF0.94. This is based on 10 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is CHF1.13, and the lowest forecast is CHF0.73. The average share price target represents a 86.41% increase from the current price of CHF0.503.
What do analysts say about Sino Biopharmaceutical?
Sino Biopharmaceutical’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Street analysts.
How can I buy shares of Sino Biopharmaceutical?
To buy shares of CH:SMZ1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.